Cure My Disease

Don't miss your cure!

 Log in / Sign up

Queensland study reveals why parents say yes or no to RSV shot for babies

NCT ID NCT07615192

Recruiting now Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study observes how many eligible infants in Queensland receive the RSV immunisation (nirsevimab) during their first RSV season. Researchers will survey 1,200 parents to understand why they chose for or against the shot, and look at factors like location and health risks. No treatment is given—the study simply collects real-world data to improve future vaccination programs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could help public health officials understand RSV vaccine uptake and improve immunisation strategies for infants.
What could go wrong
This is an observational study, not a treatment trial. It only measures current vaccination rates and parent attitudes, so it won't directly change health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RSV IMMUNIZATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RSV IMMUNIZATION

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Paratus Clinical Research

    RECRUITING

    Brisbane, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.